At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02591 INNOGEN-B
Not Yet Opened 01-13 16:08:11
31.820
+0.740
+2.38%
High32.500
Low30.520
Vol439.06K
Open30.520
D1 Closing31.080
Amplitude6.37%
Mkt Cap14.54B
Tradable Cap13.37B
Total Shares457.00M
T/O13.92M
T/O Rate0.10%
Tradable Shares420.29M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
HK Stock Movement | INNOGEN-B (02591) Rises Over 3% Intraday as Esupaglutide α Recommended in National Diabetes Prevention Guidelines
Guangzhou Innogen Pharmaceutical Group Co Ltd is a China-based investment holding company principally engaged in the research, development and commercialisation of pharmaceutical products. The Company is primarily engaged in the commercialization of innovative, humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. The Company is dedicated to developing therapies for diabetes and other metabolic diseases. The Company’s core product, Efsubaglutide Alfa (brand name: Diabegone), is used for the treatment of type 2 diabetes (T2D). The Company’s primary pipeline drug candidates include YN014, YN401, YN209, YN203, and YN202. The Company principally conducts its businesses in the domestic market.